ArticleMolecular pathology : MP2002
Expression of complement regulating factors in gastric cancer cells.
Article in Molecular pathology : MP, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study.World journal of surgical oncology · 2025Article
- Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers · 2024Review
- Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.Scientific reports · 2023Article
- Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells.Chonnam medical journal · 2023Article
- CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity.Scientific reports · 2022Article
- Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis.JCI insight · 2022Article
- Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.Cancer research · 2021Review
- Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors.OncoTargets and therapy · 2019Article
- Role of C5b-9 and RGC-32 in Cancer.Frontiers in immunology · 2019Review
- Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.Oncolytic virotherapy · 2019Review
- Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.Scientific reports · 2018Article
- Beyond the Role of CD55 as a Complement Component.Immune network · 2018Review
- Prognostic Significance of Preoperative and Postoperative Complement C3 Depletion in Gastric Cancer: A Three-Year Survival Investigation.BioMed research international · 2017Observational
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.mAbs · 2014Review
- Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.Immunologic research · 2013Review
- The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.PloS one · 2012Article
- Article
- Membrane attack by complement: the assembly and biology of terminal complement complexes.Immunologic research · 2011Review
- Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation.International journal of inflammation · 2010Article
- Complement decay accelerating factor (DAF)/CD55 in cancer.Cancer immunology, immunotherapy : CII · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the deposition of complement components, C3d and C5b-9, and the expression of complement regulating factors (S protein, membrane cofactor protein (MCP; CD46), protectin (CD59), decay accelerating factor (DAF; CD55), and type 1 complement receptor (CR1; CD35)) in gastric cancers.
methodsSpecimens of gastric cancer were examined by immunohistochemistry and immunoelectron microscopy.
resultsFour complement regulating factors (S protein, MCP, protectin, and DAF) were expressed on gastric cancer cells, in ultrastructurally localised areas on the cell membrane. CR1 was not expressed. The staining intensity of DAF in both differentiated and undifferentiated adenocarcinomas was significantly higher than in histologically normal gastric epithelium. Furthermore, the staining intensity of DAF in gastric cancers showing a diffusely infiltrating growth pattern was higher than in gastric cancers showing an expanding growth pattern.
conclusionsThese data indicate that DAF may play a role in cancer cell infiltration and resistance in tumour cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.